CTIS2022-502161-19-00招募中1 期
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines - CLOU064A2304
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 468
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Male and female adult participants =18 years of age at the time of signing the informed consent., CSU duration for = 6 months prior to screening., Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of randomization, defined as: •The presence of itch and hives for =6 consecutive weeks prior to screening, despite the use of second-generation H1-AH during this time period. •UAS7 score (range 0-42) =16, ISS7 score (range 0-21) = 6 and HSS7 score (range 0- 21) = 6 during the 7 days prior to randomization (Day 1)., Documentation of hives within three months before randomization., Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol., Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1).
排除标准
- •Prior exposure to ligelizumab, omalizumab and other biologics with any effect in CSU, including anti-IgE therapies., Significant bleeding risk or coagulation disorders., History of gastrointestinal bleeding., Requirement for anti-platelet or anti-coagulant medication., History or current hepatic disease., Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant., Evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines., Documented history of anaphylaxis.
研究者
相似试验
尚未招募
3 期
A study to see how safe and how effective remibrutinib is for people suffering from urticariaCTRI/2024/01/061601ovartis Healthcare Pvt Ltd
尚未招募
3 期
A global Phase III clinical trial of recombinant COVID-19 vaccine (Sf9 cells) in adults aged 18 years and olderCoronavirus disease COVID-19PACTR202103845381761Chengdu WestVac Biopharm Co Ltd40,000
进行中(未招募)
1 期
Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective SurgeryGeneral anaesthesiaMedDRA version: 21.1Level: PTClassification code: 10018060Term: General anaesthesia Class: 100000004865CTIS2023-507009-32-00Haisco-USA Pharmaceuticals Inc.399
进行中(未招募)
不适用
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic Paidiabetic neuropathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2007-001140-47-CZAbbott GmbH & Co. KG110
进行中(未招募)
1 期
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic Paidiabetic neuropathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2007-001140-47-FRAbbott GmbH & Co. KG110
